On August 13, 2026, the clinical trial registry listed an update for a study involving cosyntropin. The trial, titled "Subclinical Primary Aldosteronism in Diabetes At-Risk for Kidney Disease," is registered under identifier NCT06190158.
The study is classified as Early Phase 1. Its current status is listed as active, not recruiting, meaning the trial is ongoing but is not currently enrolling new participants.
This update reflects a change in trial status only. No results have been posted for this study as part of this update, and no outcome data accompanies this status change. The trial title indicates a focus on subclinical primary aldosteronism among individuals with diabetes who are considered at risk for kidney disease, but the specific objectives, endpoints, and methodology are governed by the full trial protocol on the registry.
Readers interested in this study can consult the official clinical trial registry entry for complete details on design, eligibility, and any future updates regarding results or status changes. For more background on cosyntropin, including its approved regulatory status and general information, see the compound overview.